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Dose intensity in chemotherapy is defined as the amount of drug
delivered per unit time. Bonadonna and Valgussa found in 1981
that disease-free survival was shorter in node-positive breast
cancer patients who received a reduced dose of adjuvant
chemotherapy consisting of cyclophosphamide, methotrexate and
fluorouracil (CMF) than in those who received full or nearly full
dose (Bonadonna and Valagussa, 1981) Similar findings have been
published in other retrospective studies in early and advanced
breast cancer (Rodriguez et al, 1981; Tormey et al, 1983; Howell
et al, 1984; Senn et al, 1984; Ang et al, 1989; Pronzato et al, 1989)
while in some studies no significant correlation between the given
dose and survival benefit was found (Ahmann et al, 1982;
Glucksberg et al, 1982; Redmond et al, 1983; Mouridsen et al,
1984; Velez-Garcia et al, 1987). These studies have been criticized
due to the bias inherent in this kind of retrospective analysis
(Redmond et al, 1983). Patients with a larger tumour burden may
tolerate chemotherapy poorly due to the presence of occult bone
marrow metastases and may receive a lower total dose. This may
create a false association between a low dose intensity and poor
outcome.
Only a few controlled prospective studies of the dose–response
relationship in breast cancer have been published, and the results
have not been consistent. Only one study has shown evidence of
benefit in the adjuvant setting for conventional doses as compared
to doses lower than conventional (Wood et al, 1994). Two
controlled studies have failed to demonstrate any dose–response
relationship (Fumoleau et al, 1993; Fisher et al, 1997). Only one of
these studies, studying escalated versus conventional doses (Fisher
et al, 1997) has, however, been sufficiently large to detect the
expected difference of a few per cents between the treatment
groups.
Haematological toxicity is the most important dose-limiting
toxicity and often the reason for a dose reduction. By studying the
association between experienced toxicity and outcome, the bias
associated with the retrospective studies can be circumvented. We
found in a previous study that a low leucocyte nadir during adju-
vant chemotherapy comprising cyclophosphamide, doxorubicin
and oral fthorafur (CAFt) in stage II and III breast cancer patients
associated with a long distant disease-free (DDFS) and overall
survival (OS) (Saarto et al, 1997). Similar findings were also
reported in a study by Ahman et al (1982).
CMF is perhaps the most widely used chemotherapy combina-
tion in adjuvant treatment of breast cancer. We, therefore, wanted
to study whether high haematological toxicity was associated with
a better outcome also with the CMF regimen.
MATERIALS AND METHODS
Patients
The study population comprised of 368 consecutive pre- and peri-
menopausal women with primary T1–4 histologically proven
node-positive breast cancer, without distant metastases. All
patients were treated with post-operative adjuvant CMF between
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All patients underwent sur gery with axillary clearance and total
mastectomy or breast-conserving resection. Patients were treated
with adjuvant chemotherapy , which consisted of six cycles of
cyclophosphamide (600 mg m –2), methotrexate (40 mg m –2) and
fluorouracil (600 mg m –2) administered intravenously on day 1 at
3 -week intervals. A total of 363 patients underwent post-operative
irradiation, and 63 received adjuvant tamoxifen. The majority of
patients who received radiotherapy had irradiation to the regional
lymph nodes and operative scar or the remaining breast with
megavoltage irradiation (45–50 Gy in 18–25 fractions) after the
second or the third cycle of chemotherapy , or after six cycles of
chemotherapy.
Staging investigations included clinical investigation, liver
enzymes, chest X-ray , liver scintigraphy or ultrasound and bone
scintigraphy . The white blood cell counts, haemoglobin and
thrombocytes were investigated during chemotherapy , 1 day
before treatment and approximately on day 16 of the cycle (s.d.
4.7). After treatment the patients were followed up at 3- to 4-
month intervals for the first 2 years and thereafter at 6-month
intervals for at least 5 years. After the fifth year of follow-up the
control visits were performed once a year . The control examina-
tions included clinical investigation, liver enzymes and serum
creatinine at 3- to 6-month intervals. A bone scan, liver ultrasound
and chest X-ray were performed only upon suspicion of recur-
rence. The median follow-up time was 68 months (range 5–126).
Data for 19 patients were excluded from the analyses because
nine patients had disease progression during chemotherapy , nine
patients received fewer than four chemotherapy cycles, and one
patient had missing data on leucocyte nadir values. Therefore,
349 patients were eligible for analysis. Six patients had missing
data on the relative dose intensity . Ten patients with other
histology than ductal or lobular cancer were excluded from the
prognostic analysis of the histological type.
Calculation of haematological toxicity and leucocyte
nadir
For analyses of the ef fect of haematological toxicity on DDFS and
OS we used the minimum leucocyte count, which was the lowest
leucocyte count measured during the entire course of
chemotherapy.
Definitions and calculation of doase intensity
The doses of each chemotherapy drug, the duration of treatment
and the body surface area were extracted from the patient records.
The absolute dose intensity was defined as the amount of drug
administered per unit body surface area (mg m–2) delivered per
unit time (mg m–2 week–1). The relative dose intensity was calcu-
lated as the delivered dose intensity divided by the projected dose
intensity, according to Longo et al (1991). The projected dose
intensity is the total amount of drugs scheduled in the protocol,
divided by the projected time schedule of the entire treatment.
The delivered dose intensity represents the total amount of drug
actually received, divided by the time taken for the therapy . Dose
intensities for each drug were calculated for the total number of
cycles (DI). Duration of treatment was defined as the interval (in
weeks) between day 1 of the first cycle of chemotherapy and day
21 of the last given cycle.
For example, for a patient who received 450 mg m –2
cyclophosphamide and 35 mg m –2 methotrexate (five cycles
during22 weeks), the dose intensity of cyclophosphamide is
((450mg m–2 ´ 5) / 22 weeks) / 150mg m –2 / week = 0.68 = 68%
and dose intensity of methotrexate is ((35 mg m –2 ´ 5) / 22 weeks)/
11.7mg m–2/week = 0.68 = 68%.
Statistical methods
Life tables were calculated according to Kaplan–Meier (Kaplan
and Meier, 1958). The statistical significance of the dif ference
between the survival curves was calculated using the log-rank test
(Peto et al, 1977) and Cox regression analysis (Cox, 1972). Only
deaths due to breast cancer were scored as events in the analysis of
OS. In the univariate and multivariate survival analysis the covari-
ates were entered according to the categories presented in T ables 1
and 2. Multivariate survival analyses were performed by entering
the leucocyte nadir as a continuous and a categorical variable.
Covariates were selected in a backward stepwise fashion, with the
use of the maximum-likelihood ratio. A P -value of 0.05 was
adopted as the limit for inclusion of a covariate.
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Table 1Cox univariate distant disease-free survival analysis in patients with
node-positive breast cancer
n RR Cl 95% P-value
Leucocyte nadir tertiles
Lowest  115  1
Middle 122 1.29  0.84–1.98  0.25
Highest  112 1.64  1.08–2.48  0.02
Leucocyte nadir continuous  349  1.31  1.04–1.64  0.02
Axillary lymph nodes
1–3  232  1
> 3  106 2.56  1.82–3.59  < 0.0001
Tumour size
T1 139  1
T2 169  2.55  1.69–3.84  < 0.0001
T3  33  4.17  2.44–7.14  < 0.0001
Progesterone receptor
Positive  186  1
Negative  114  2.28  1.60–3.25  < 0.0001
Oestrogen receptor
Positive  186  1
Negative  121 2.04  1.44–2.88  < 0.0001
Surgical procedure
Resection  75  1
Mastectomy  274  2.72  1.59–4.64  0.0003
Tamoxifen
No 287  1
Y es  61 1.80  1. 11–2.93  0.02
Grade
118 1
2 102 3.03  0.94–9.77  0.06
3  78  3.96  1.22–12.86  0.02
Histologic type
Ductal 302  1
Lobular  37  1.98  1.01–3.90  0.05
Age
35–49  271  1
³50  47  1.13  0.69–1.85  0.62
< 35  31  2.12  1.30–3.46  0.003RESULTS
The median number of chemotherapy cycles given was six. The
mean total dose of cyclophosphamide was 90% (range 42–104%)
of the planned total dose, the mean total dose of methotrexate was
94% (range 36–123%) and that of fluorouracil 90% (range
47–103%). The mean relative dose intensity of cyclophosphamide
was 85% (range 39–113%), methotrexate 88% (range 37–119%)
and fluorouracil 84% (range 20–116%). The main reason for dose
reduction was leucopenia (n = 45, 13%). Other such reasons were
skin erythema due to radiotherapy and elevated liver enzymes. The
main reason for a low dose intensity was a break in chemotherapy
caused by radiotherapy. The mean leucocyte nadir value was 2.3
(s.d. 0.7, range, 0.6–5.1). The nadir leucocyte tertiles were less
than 2.0, 2.0–2.7 and greater than 2.7. The overall dose intensity
was similar in all leucocyte tertile groups (mean: 88%, 87% and
87% for the lowest, middle and highest third respectively)
Univariate analysis
In univariate analyses there was a significant association between
a low leucocyte nadir and a long DDFS (P = 0.02 both when
analysed by the log-rank test for a trend as tertiles and when tested
as a continuous variable by Cox regression analysis) (Figure 1).
Other factors significantly associated with a long DDFS in a
univariate analysis were a low number of metastatic lymph nodes,
a small tumour size, positive oestrogen and progesterone receptor
status, breast-conserving surgical procedure, adjuvant tamoxifen
therapy, low differentiation grade, ductal histological type, and age
between 35 and 49 (Table 1). The relative dose intensity was not
significantly associated with DDFS. Patients with a low leucocyte
nadir tended to have a longer OS in a univariate analysis
(P = 0.06). When restricted to patients with a nadir value taken
during days 9–14 (n = 99) the association between leucopenia and
DDFS (risk ratio 1.56, P = 0.05) was stronger than in the entire
series (risk ratio 1.31, P = 0.02)
Multivariate analysis
All variables which were significantly associated to DDFS or OS
in a univariate analysis were included in a multivariate analysis.
The nodal status, tumour size, progesterone receptor status, the
type of surgery (mastectomy or conservative resection), age and
tamoxifen therapy were significantly associated with DDFS
(Table 2), while the leucocyte nadir lost its significance. In
analyses of OS the number of affected lymph nodes, tumour size,
oestrogen and progesterone receptor status, the type of surgery and
age were independent prognostic factors.
We also tested the correlation among different variables by c2
method. The only variable which correlated with leucocyte nadir
was age (P = 0.03). Patients aged 44 years or older had higher
leucocyte nadir values than younger patients. Tumour size, nodal
status, steroid receptor status, tamoxifen therapy, histological type,
grade or surgical procedure had no correlation with leucocyte
nadir.
DISCUSSION
To our knowledge there are no published controlled trials testing
the dose intensity of CMF in the adjuvant setting. In a recent study
(Wood et al, 1994), however, low dose chemotherapy produced
inferior results when compared to conventional dose cyclophos-
phamide, adriamycin and fluorouracil as adjuvant chemotherapy
in node-positive breast cancer. On the other hand, in another
adjuvant study with more than 2000 randomized patients even a
fairly large increase in the dose intensity of cyclophosphamide
resulted in only increased toxicity without any survival benefit
(Fisher et al, 1997).
Several retrospective analyses of dose intensity of CMF in the
adjuvant setting have been published, but these can be criticized
for statistical bias. Patients with poor tolerance to chemotherapy,
e.g. due to subclinical metastases and low performance status,
may receive lower doses. This may create a false positive
dose–response association. This is not likely the case with the
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Table 2 Multivariate distant disease-free survival analysis in 283 patients
with node-positive breast cancer. Recurrent breast cancer was detected in
115 (41%) of these patients at the end of follow-up
RR Cl 95% P-value
Axillary lymph nodes
1–3 1.00
> 3 2.56 1.76–3.74 < 0.0001
Tumour size
T1 1.00
T2 2.02 1.28–3.16 0.002
T3 2.66 1.45–4.88 0.002
Progesterone receptor
Positive 1.00
Negative 2.20 1.48–3.26 < 0.0001
Surgical procedure
Resection 1.00
Mastectomy 3.23 1.72–6.09 0.0003
Age
35–49 1.00
³ 50 0.82 0.46–1.47 NS
< 35 2.38 1.38–4.07 0.002
Tamoxifen
Yes 1.00
No 2.11 1.20–3.72 0.009
Leucocyte nadir tertiles NS
Oestrogen receptor NS
Histologic type NS
Grade NS
NS, not significant.
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Figure 1 Distant disease-free survival according to leucocyte tertiles in
patients with node-positive breast cancerpresent retrospective analysis of toxicity as a surrogate marker of
dose effect, because patients who have leucopenia due to sub-
clinical bone marrow metastases are expected to decrease the
association between leucopenia and favourable DDFS.
Earlier we found an association between a low leucocyte nadir
and a high overall survival rate among 211 breast cancer patients
who were treated with doxorubicin-based adjuvant chemotherapy
(CAFt) (Saarto et al, 1997). In the present study, a similar associa-
tion was found for the CMF regimen, but the association was,
however, relatively weak. There may be several explanations for
this. The study population comprises patients who were treated
with routine adjuvant CMF therapy, and the timing of leucocyte
nadir tests varied. Actually, the association between DDFS and
degree of leucopenia was stronger if the analyses were restricted to
patients whose nadir values fell between days 9 and 14 of the
cycle. Even if the association between the leucocyte nadir and
outcome is due to individual differences in the treatment effect, the
association is expected to be weak as compared to other prognostic
variables. According to the results from the EBCTCG overview
study the difference in 10-year recurrence-free survival was 25%
between nodal negative and positive groups, while adjuvant
CMF improved 10-year recurrence-free survival with only 8%
(Anonymous, 1992).
The leucocyte nadir was not an independent prognostic factor in
a multivariate survival analysis. We did not, however, find any
significant correlation between the nadir and other prognostic vari-
ables. Most of the other known prognostic factors have a stronger
effect on outcome than adjuvant chemotherapy. Thus, if the
leucocyte nadir is used as a marker of chemotherapy effect, it is
not expected to be as strong as other variables entered, and may,
therefore, easily fall out of the final prognostic model.
In a recent study by Colleoni et al (1998), reductions larger than
35% in the dose administered, oral CMF adversely influenced
outcome of breast cancer patients. The best outcome was in the
intermediate dose group, which received 65–85% of the intended
dose. Colleoni et al considered that it may be postulated that for
adjuvant chemotherapy the clinically achieved effect, as evidenced
by moderate toxicity, better correlates with survival than the total
dose delivered.
The results of the present study suggest that leucopenia could be
used as a biological indicator of an effective chemotherapy dose.
Whether the outcome of those patients who do not experience
leucopenia can be improved by dose-escalation can only be
studied in a randomized trial.
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